Sign in
Companies / PODD vs DXCM

PODD vs DXCM: Insulet and Dexcom

Medical Devices
Compare more companies

Insulet (PODD) reported $2.7B in revenue against a 9.1% net margin, while Dexcom (DXCM) reported $4.7B at a 17.9% net margin, most recently.

MetricPODDDXCM
Revenue$2.7B$4.7B
Net Income$0.2B$0.8B
Gross Margin71.6%60.1%
Operating Margin17.5%19.6%
EPS (Diluted)$3.48$2.09
Free Cash Flow$0.4B$1.1B
Total Debt$0.9B$1.3B
P/E Ratio81.7×31.8×
P/B Ratio13.2×9.3×
Stock Price$153.92$84.45
Free: last 5 years
Fiscal yearFY2009 🔒FY2010 🔒FY2011 🔒FY2012 🔒FY2013 🔒FY2014 🔒FY2015 🔒FY2016 🔒FY2017 🔒FY2018 🔒FY2019 🔒FY2020 🔒FY2021FY2022FY2023FY2024FY2025
PODD Revenue••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$1.1B$1.3B$1.7B$2.1B$2.7B
DXCM Revenue••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$2.4B$2.9B$3.6B$4.0B$4.7B

More on PODD

More on DXCM

Other comparisons